{"id":9056,"date":"2019-11-18T20:14:00","date_gmt":"2019-11-18T20:14:00","guid":{"rendered":"https:\/\/polpharmabiologics.com\/?p=9056"},"modified":"2025-03-25T15:39:37","modified_gmt":"2025-03-25T15:39:37","slug":"first-subjects-in-ph-iii-study-with-pb006-proposed-biosimilar-to-natalizumab-have-been-randomized","status":"publish","type":"post","link":"https:\/\/polpharmabiologics.com\/pl\/first-subjects-in-ph-iii-study-with-pb006-proposed-biosimilar-to-natalizumab-have-been-randomized\/","title":{"rendered":"First subjects in ph III study with PB006 (proposed Biosimilar to Natalizumab) have been randomized."},"content":{"rendered":"\n<p>Our phase III clinical trial (PB006-03-01) entered into the stage when first patients were treated with study medication.<\/p>\n\n\n\n<p>This study is conducted in 7 countries in and outside Europe including Poland. First participants were included in the study at the clinical site in Katowice (Poland).<\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/polpharmabiologics.com\/uploads\/post\/polpharma_linkedin_1.png\" alt=\"\"\/><\/figure>\n\n\n\n<p>The study, managed by&nbsp;<strong>Hendrik Wessels<\/strong>, Polpharma Biologics Clinical Development team, led by<strong>&nbsp;Karsten Roth<\/strong>, Director Clinical Research &amp; Development, is an essential part of the development program for the proposed Biosimilar to Natalizumab.<\/p>\n\n\n\n<p>More information can be found&nbsp;<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04115488\">here<\/a>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Our phase III clinical trial (PB006-03-01) entered into the stage when first patients were treated with study medicat&#8230;<\/p>\n","protected":false},"author":7,"featured_media":7352,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[34],"class_list":["post-9056","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-artykuly","tag-aktualnosci-firmowe"],"_links":{"self":[{"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/posts\/9056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/comments?post=9056"}],"version-history":[{"count":0,"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/posts\/9056\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/media\/7352"}],"wp:attachment":[{"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/media?parent=9056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/categories?post=9056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/polpharmabiologics.com\/pl\/wp-json\/wp\/v2\/tags?post=9056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}